Other Events ·
At its 2026 Annual Meeting on July 20, 2026, TransCode Therapeutics, Inc. stockholders approved several material items
RNAZTranscode Therapeutics, Inc.
At its 2026 Annual Meeting on July 20, 2026, TransCode Therapeutics, Inc. stockholders approved several material items. These include the issuance of common stock upon the conversion of Series A, B, and C Non-Voting Convertible Preferred Stock, and the issuance of common stock under a Standby Equity Purchase Agreement and convertible promissory notes with YA II PN, Ltd. Additionally, stockholders approved increasing the 2021 Stock Option and Incentive Plan by 1,734,262 shares. The company also elected six directors and ratified WithumSmith+Brown, PC as its independent auditor. TransCode Therapeutics is a biotechnology company that develops therapeutic candidates.